Biosimilars Switching Policies in Canada

Goodwin
Contact

Goodwin

Further to our post last week on British Columbia’s policy requiring “switching” patients taking Humira, the Alberta government has also implemented a policy, effective May 1, 2021, of requiring that patients over the age of 18 taking Humira switch to one of five adalimumab biosimilars approved by Health Canada:  Amgevita, Hadlima, Hulio, Hyrimoz, and Idacio.  These patients have until May 1, 2022, to switch to a biosimilar adalimumab; about 3,300 patients are expected to be impacted.  According to Alberta Blue Cross, “Alberta spent more than $238 million in the 2018 to 2019 fiscal year on biologic drugs and these costs are increasing every year.  Costs per patient for originator biologics can be more than $25,000 per patient per year, with biosimilar versions costing up to 50 per cent less than originator biologics.”

Alberta’s switching policy is an extension of its biosimilar initiatives, established in December 2019, to expand the use of biosimilar medicines under the province’s public drug plans.  So far, patients in Alberta have been switched from Remicade (infliximab), Enbrel (etanercept), Lantus (insulin glargine), Neulasta (pegfilgrastim), Neupogen (filgrastim), and Rituxan (rituximab).  Other provinces, including British Columbia and New Brunswick, have similar biosimilars switching policies.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.